TNFRSF10B and neoplasm: The key novelty of this work lies in the synergistic combination of a proteasome inhibitor (BTZ) with a DR5-selective apoptotic ligand within a single, pH-responsive amphiphilic AmphPVP carrier, further enhanced by a tumor-penetrating peptide (iRGD).